BioTime Inc. (BTX)

1.17
AMEX : Health Technology
Prev Close 1.20
Day Low/High 1.10 / 1.20
52 Wk Low/High 0.66 / 2.61
Avg Volume 806.70K
Exchange AMEX
Shares Outstanding 149.64M
Market Cap 179.57M
EPS -0.40
P/E Ratio 3.00
Div & Yield N.A. (N.A)
BioTime, Inc. Announces Closing Of Public Offering And Underwriters' Full Exercise Of Over-Allotment Option

BioTime, Inc. Announces Closing Of Public Offering And Underwriters' Full Exercise Of Over-Allotment Option

BioTime, Inc. ("BioTime") (NYSE American and TASE: BTX), a late stage clinical biotechnology company focused on developing and commercializing products addressing degenerative diseases, today announced the closing of its...

BioTime, Inc. Announces Pricing Of $25.0 Million Public Offering Of Common Stock

BioTime, Inc. Announces Pricing Of $25.0 Million Public Offering Of Common Stock

BioTime, Inc. ("BioTime") (NYSE American and TASE: BTX), a late stage clinical biotechnology company focused on developing and commercializing products addressing degenerative diseases, today announced the pricing of an...

BioTime, Inc. Announces Proposed Public Offering Of Common Stock

BioTime, Inc. Announces Proposed Public Offering Of Common Stock

BioTime, Inc. ("BioTime") (NYSE American and TASE: BTX), a late stage clinical biotechnology company focused on developing and commercializing products addressing degenerative diseases, today announced its intent to offer...

BioTime Announces First Patient In U.S. Clinical Trial Treated For Facial Volume Deficit

BioTime Announces First Patient In U.S. Clinical Trial Treated For Facial Volume Deficit

BioTime, Inc. (NYSE American: BTX), a late stage clinical biotechnology company focused on developing and commercializing products addressing degenerative diseases, today reported that an investigator-led clinical trial has...

BioTime And Processa Announce Their Intention To Enter Into A HyStem® Sublicense For Drug Delivery

BioTime And Processa Announce Their Intention To Enter Into A HyStem® Sublicense For Drug Delivery

BioTime, Inc. (NYSE American: BTX), a late stage clinical biotechnology company focused on developing and commercializing products addressing degenerative diseases, today reached agreement on terms to sublicense certain...

BioTime To Present At The Cell And Gene Meeting On The Mesa

BioTime To Present At The Cell And Gene Meeting On The Mesa

BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases, today announced that Jim Knight, SVP, Head of Corporate...

BioTime Announces Positive Secondary And Additional Positive Long-Term Data From The Renevia® Pivotal Trial

BioTime Announces Positive Secondary And Additional Positive Long-Term Data From The Renevia® Pivotal Trial

BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases, today announced that treated patients from the Renevia ®...

BioTime Board Of Directors Approves Distribution Of AgeX Therapeutics Shares To BioTime Shareholders

BioTime Board Of Directors Approves Distribution Of AgeX Therapeutics Shares To BioTime Shareholders

BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases, announced today that its Board of Directors has approved a...

BioTime Co-CEO Adi Mohanty To Participate In Panel Discussion At The Cell & Gene Therapy CEO Forum

BioTime Co-CEO Adi Mohanty To Participate In Panel Discussion At The Cell & Gene Therapy CEO Forum

BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases, today announced that Co-Chief Executive Officer Adi...

AgeX Therapeutics CEO Michael D. West To Participate In Fireside Chat With J. Craig Venter At The Cell & Gene Therapy CEO Forum

AgeX Therapeutics CEO Michael D. West To Participate In Fireside Chat With J. Craig Venter At The Cell & Gene Therapy CEO Forum

AgeX Therapeutics, Inc. ( AgeX), a subsidiary of BioTime, Inc.

BioTime To Present At The Ladenburg Thalmann 2017 Healthcare Conference

BioTime To Present At The Ladenburg Thalmann 2017 Healthcare Conference

BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases, today announced that Adi Mohanty, Co-Chief Executive Officer,...

BioTime To Present At The Cantor Fitzgerald Global Healthcare Conference

BioTime To Present At The Cantor Fitzgerald Global Healthcare Conference

BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases, today announced that Adi Mohanty, Co-Chief Executive Officer,...

BioTime Awarded Grant From The NIH

BioTime Awarded Grant From The NIH

BioTime, Inc. (NYSE American:BTX), a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases, today announced that it has been awarded a grant of up to $1.

Two Key BioTime Patents Providing Protection To OpRegen® Remain Upheld

Two Key BioTime Patents Providing Protection To OpRegen® Remain Upheld

BioTime, Inc. (NYSE American: BTX), a clinical stage biotechnology company focused on developing and commercializing products addressing degenerative diseases, and its subsidiaries, today announced the successful conclusion...

BioTime To Present At The Rodman & Renshaw Annual Global Investment Conference

BioTime To Present At The Rodman & Renshaw Annual Global Investment Conference

BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases, today announced that Adi Mohanty, Co-Chief Executive Officer,...

BioTime To Present At The LD Micro San Francisco Summit

BioTime To Present At The LD Micro San Francisco Summit

BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases, today announced that Jim Knight, Senior Vice President, Head of...

BioTime To Present Data At The Military Health System Research Symposium

BioTime To Present Data At The Military Health System Research Symposium

BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases, today announced that it will be presenting one podium...

AgeX Therapeutics Closes $10 Million Capital Raise

AgeX Therapeutics Closes $10 Million Capital Raise

AgeX Therapeutics, Inc. ( AgeX), a subsidiary of BioTime, Inc.

BioTime Announces $2 Million Grant For Further Development Of OpRegen® For Dry-AMD

BioTime Announces $2 Million Grant For Further Development Of OpRegen® For Dry-AMD

BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases, has been awarded a new grant for 2017 of up to 7.

AgeX Therapeutics CEO Michael D. West, Ph.D. To Deliver Keynote Address On Biotechnology And Aging At RAAD Festival

AgeX Therapeutics CEO Michael D. West, Ph.D. To Deliver Keynote Address On Biotechnology And Aging At RAAD Festival

AgeX Therapeutics, Inc. ( AgeX), a subsidiary of BioTime, Inc.

BioTime Reports Second Quarter Results And Recent Corporate Accomplishments

BioTime Reports Second Quarter Results And Recent Corporate Accomplishments

BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today reported financial results for the second quarter ended June 30,...

AgeX Therapeutics Obtains $10 Million In Capital And Commences Operations

AgeX Therapeutics Obtains $10 Million In Capital And Commences Operations

AgeX Therapeutics, Inc. (AgeX), a subsidiary of BioTime, Inc.

BioTime Receives DSMB Approval To Start Third Patient Cohort In Clinical Trial For Dry-AMD; Commences Patient Enrollment In The US

BioTime Receives DSMB Approval To Start Third Patient Cohort In Clinical Trial For Dry-AMD; Commences Patient Enrollment In The US

BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that the Data Safety Monitoring Board (DSMB) has authorized the...

BioTime, Inc. To Announce Second Quarter 2017 Results On August 2, 2017

BioTime, Inc. To Announce Second Quarter 2017 Results On August 2, 2017

BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that it will release second quarter financial and operating...

Data From BioTime's Phase I/IIa OpRegen® Trial To Be Presented At The 2017 American Academy Of Ophthalmology (AAO) Annual Meeting

Data From BioTime's Phase I/IIa OpRegen® Trial To Be Presented At The 2017 American Academy Of Ophthalmology (AAO) Annual Meeting

BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that an abstract related to the Company's retinal tissue...

BioTime To Host Key Opinion Leader Event On The Topic Of Dry AMD In New York City

BioTime To Host Key Opinion Leader Event On The Topic Of Dry AMD In New York City

BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, announced today that it will host a Key Opinion Leader event on the topic of...

BioTime Subsidiary AgeX Therapeutics Appoints Aubrey De Grey, Ph.D. As VP Of New Technology Discovery

BioTime Subsidiary AgeX Therapeutics Appoints Aubrey De Grey, Ph.D. As VP Of New Technology Discovery

AgeX Therapeutics ("AgeX"), a subsidiary of BioTime, Inc. (NYSE MKT:BTX) with a focus on developing new therapies in the field of biomedical gerontology, today announced the appointment of distinguished researcher and...

Biotime Expands & Advances Ophthalmology Portfolio

BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today reported several developments for its ophthalmology portfolio including:...

BioTime's Renevia® Achieves Primary Endpoint In European Pivotal Trial

BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today reported that, based on the analysis of top line data, the Renevia®...

BioTime To Announce Top Line Data From The Company's Renevia European Pivotal Trial

BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that it will report the top line data from the Company's...

TheStreet Quant Rating: D (Sell)